Noonan syndrome: genes and variants
Explore variant evidence for Noonan syndrome across 25 analyzed proteins (PTPN11, SOS1, RIT1, KRAS, RAF1 and 20 more). Linked ClinVar records include 164 pathogenic or likely pathogenic variants, 800 variants of uncertain significance and 180 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Source labels are pooled across this disease family.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Noonan syndrome
PTPN11: Tyrosine-protein phosphatase non-receptor type 11
Its SHP2 phosphatase activity promotes RAS-MAPK signaling downstream of many receptor tyrosine kinases and cytokine receptors. Germline dysregulating variants cause Noonan-spectrum disorders, while somatic activating variants drive juvenile myelomonocytic leukemia and other cancers.
44 ClinVar pathogenic / likely pathogenic and 54 uncertain variants in PTPN11 have source records linked to Noonan syndrome. Association strength is not clinical gene validity.
SOS1: Son of sevenless homolog 1
It activates RAS by exchanging GDP for GTP downstream of receptor tyrosine kinases. Germline activating variants are a common cause of Noonan syndrome, while excessive SOS1-RAS signaling can contribute to cancer.
30 ClinVar pathogenic / likely pathogenic and 110 uncertain variants in SOS1 have source records linked to Noonan syndrome. Association strength is not clinical gene validity.
RIT1: GTP-binding protein Rit1
It transmits growth and stress signals through RAS-MAPK and related pathways and is important in cardiovascular and nervous-system development. Germline activating variants cause Noonan syndrome, often with a high frequency of hypertrophic cardiomyopathy.
22 ClinVar pathogenic / likely pathogenic and 113 uncertain variants in RIT1 have source records linked to Noonan syndrome. Association strength is not clinical gene validity.
KRAS: GTPase KRas
A small GTPase that acts as a molecular switch in the RAS-MAPK signaling pathway. By cycling between GDP- and GTP-bound states, it relays growth and survival signals, and activating KRAS variants are common drivers of cancer.
16 ClinVar pathogenic / likely pathogenic and 6 uncertain variants in KRAS have source records linked to Noonan syndrome. Association strength is not clinical gene validity.
RAF1: RAF proto-oncogene serine/threonine-protein kinase
It relays activated RAS signals to MEK and ERK and also participates in survival and developmental pathways. Germline activating variants cause Noonan syndrome and related RASopathies, while oncogenic activation contributes to selected cancers.
14 ClinVar pathogenic / likely pathogenic and 35 uncertain variants in RAF1 have source records linked to Noonan syndrome. Association strength is not clinical gene validity.
BRAF: Serine/threonine-protein kinase B-raf
It relays activated RAS signals through MEK and ERK to control proliferation, differentiation, and survival. Activating variants, especially V600E, drive melanoma and several other cancers and create sensitivity to pathway-directed therapies.
11 ClinVar pathogenic / likely pathogenic and 44 uncertain variants in BRAF have source records linked to Noonan syndrome. Association strength is not clinical gene validity.
NRAS: GTPase NRas
Its active GTP-bound state drives RAF-MEK-ERK and PI3K signaling downstream of growth-factor receptors. Somatic activating variants are common drivers of melanoma, leukemia, and other cancers, while germline activating variants can cause Noonan syndrome.
9 ClinVar pathogenic / likely pathogenic and 4 uncertain variants in NRAS have source records linked to Noonan syndrome. Association strength is not clinical gene validity.
SOS2: Son of sevenless homolog 2
It activates RAS by catalyzing GDP-GTP exchange downstream of growth-factor receptors. Germline activating variants cause Noonan syndrome, generally through increased RAS-MAPK signaling.
8 ClinVar pathogenic / likely pathogenic and 601 uncertain variants in SOS2 have source records linked to Noonan syndrome. Association strength is not clinical gene validity.
MAPK1: Mitogen-activated protein kinase 1
It converts upstream RAS-RAF-MEK signaling into phosphorylation of cytoplasmic and nuclear targets controlling proliferation, differentiation, and development. Germline dysregulating variants can cause neurodevelopmental RASopathy phenotypes, while pathway hyperactivation is common in cancer.
4 ClinVar pathogenic / likely pathogenic and 4 uncertain variants in MAPK1 have source records linked to Noonan syndrome. Association strength is not clinical gene validity.
HRAS: GTPase HRas
Its GTP-bound state activates RAF-MEK-ERK and other pathways downstream of growth-factor receptors. Somatic activating variants drive several cancers, while germline activating variants cause Costello syndrome.
3 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in HRAS have source records linked to Noonan syndrome. Association strength is not clinical gene validity.
MAP2K1: Dual specificity mitogen-activated protein kinase kinase 1
It phosphorylates ERK1 and ERK2 downstream of RAF and thereby propagates RAS-MAPK growth and developmental signals. Activating somatic variants occur in several cancers, while germline activating variants can cause cardio-facio-cutaneous syndrome and related RASopathies.
1 ClinVar pathogenic / likely pathogenic and 4 uncertain variants in MAP2K1 have source records linked to Noonan syndrome. Association strength is not clinical gene validity.
GJB2: Gap junction beta-2 protein
Its connexin 26 channels support potassium and metabolite recycling within the cochlea and communication across epithelial gap junctions. Biallelic pathogenic variants are among the most common causes of congenital nonsyndromic hearing loss, while dominant variants can cause syndromic deafness with skin disease.
1 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in GJB2 have source records linked to Noonan syndrome. Association strength is not clinical gene validity.
PIK3CA: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
Its p110-alpha catalytic activity generates PIP3 and activates AKT-dependent growth, survival, and metabolic signaling downstream of many receptors. Activating variants are frequent cancer drivers and, when present mosaically during development, can cause PIK3CA-related overgrowth spectrum.
1 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in PIK3CA have source records linked to Noonan syndrome. Association strength is not clinical gene validity.
MAP2K2: Dual specificity mitogen-activated protein kinase kinase 2
It works with MEK1 to activate ERK signaling downstream of RAS and RAF. Germline activating variants can cause cardio-facio-cutaneous syndrome, while acquired activation can support oncogenic MAPK signaling and drug resistance.
0 ClinVar pathogenic / likely pathogenic and 3 uncertain variants in MAP2K2 have source records linked to Noonan syndrome. Association strength is not clinical gene validity.
CBL: E3 ubiquitin-protein ligase CBL
It limits receptor-tyrosine-kinase signaling by ubiquitinating activated receptors and promoting their internalization and degradation. Germline or somatic pathogenic variants can prolong RAS-MAPK signaling and cause Noonan-like developmental disease or myeloid malignancy.
0 ClinVar pathogenic / likely pathogenic and 2 uncertain variants in CBL have source records linked to Noonan syndrome. Association strength is not clinical gene validity.
ARAF: Serine/threonine-protein kinase A-Raf
It transmits RAS signals to the MEK-ERK pathway and participates in growth and developmental signaling. Activating germline or somatic variants can cause RASopathy phenotypes and have been identified as oncogenic drivers in selected tumors.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in ARAF have source records linked to Noonan syndrome. Association strength is not clinical gene validity.
FGA: Fibrinogen alpha chain
It contributes the alpha chains of fibrinogen, which thrombin converts into fibrin to form the structural mesh of blood clots. Pathogenic variants can cause afibrinogenemia, hypofibrinogenemia, dysfibrinogenemia, thrombosis, or certain hereditary amyloidoses.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in FGA have source records linked to Noonan syndrome. Association strength is not clinical gene validity.
FGB: Fibrinogen beta chain
It contributes the beta chains required for assembly and secretion of functional fibrinogen and subsequent fibrin-clot formation. Pathogenic variants can reduce fibrinogen quantity or alter clot properties, producing bleeding, thrombosis, or both.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in FGB have source records linked to Noonan syndrome. Association strength is not clinical gene validity.
FGG: Fibrinogen gamma chain
It contributes the gamma chains of fibrinogen and provides binding sites important for fibrin polymerization, platelet interactions, and clot stabilization. Pathogenic variants can cause quantitative or qualitative fibrinogen disorders and, in some alleles, hereditary renal amyloidosis.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in FGG have source records linked to Noonan syndrome. Association strength is not clinical gene validity.
ITGA2B: Integrin alpha-IIb
Together with ITGB3, it forms the major platelet fibrinogen receptor that becomes activated during platelet stimulation and drives aggregation. Biallelic loss-of-function variants cause Glanzmann thrombasthenia, a severe inherited platelet-aggregation disorder.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in ITGA2B have source records linked to Noonan syndrome. Association strength is not clinical gene validity.
ITGB3: Integrin beta-3
In platelets it pairs with ITGA2B to bind fibrinogen and mediate aggregation, while in other cells it forms integrins involved in matrix adhesion and signaling. Biallelic loss-of-function variants cause Glanzmann thrombasthenia.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in ITGB3 have source records linked to Noonan syndrome. Association strength is not clinical gene validity.
MAPK3: Mitogen-activated protein kinase 3
It works with ERK2 to transmit growth-factor and mitogen signals to transcriptional and cytoplasmic targets. Abnormal ERK activation is a hallmark of many RAS-MAPK-driven cancers and developmental syndromes.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in MAPK3 have source records linked to Noonan syndrome. Association strength is not clinical gene validity.
SRC: Proto-oncogene tyrosine-protein kinase Src
It integrates signals from growth-factor receptors, integrins, and other surface proteins to regulate proliferation, adhesion, migration, and survival. Persistent SRC-family signaling promotes invasion and therapy resistance in many cancers and remains an important therapeutic target.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in SRC have source records linked to Noonan syndrome. Association strength is not clinical gene validity.
VCL: Vinculin
It links integrins and cadherins to the actin cytoskeleton at focal adhesions and adherens junctions, transmitting mechanical force between cells and matrix. Pathogenic variants can cause dilated or hypertrophic cardiomyopathy and, in some cases, skeletal myopathy.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in VCL have source records linked to Noonan syndrome. Association strength is not clinical gene validity.
VWF: von Willebrand factor
It tethers platelets to damaged vessel walls and carries factor VIII in the circulation, linking primary hemostasis with coagulation. Quantitative or qualitative pathogenic variants cause von Willebrand disease, the most common inherited bleeding disorder.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in VWF have source records linked to Noonan syndrome. Association strength is not clinical gene validity.
Weakly linked (only a few uncertain records): CDC42.
Where Noonan syndrome variants cluster
- PTPN11 SH2 1 (positions 6–102): 17 of 41 ClinVar pathogenic / likely pathogenic variants, 2.5× more than its size predicts (a length-based count, not a validated hotspot).
- SOS2 DH (positions 198–388): 6 of 8 ClinVar pathogenic / likely pathogenic variants, 5.2× more than its size predicts (a length-based count, not a validated hotspot).
- BRAF Phorbol-ester/DAG-type (positions 234–280): 4 of 11 ClinVar pathogenic / likely pathogenic variants, 5.9× more than its size predicts (a length-based count, not a validated hotspot).
ClinVar pathogenic and likely pathogenic variants linked to Noonan syndrome
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| PTPN11 R498Q | 498 | Tyrosine-protein phosphatase | Pathogenic / likely pathogenic (★★★★) |
| SOS1 M269T | 269 | DH | Pathogenic / likely pathogenic (★★★) |
| SOS1 R552K | 552 | Pathogenic / likely pathogenic (★★★) | |
| SOS1 R552G | 552 | Pathogenic / likely pathogenic (★★★) | |
| SOS1 R552T | 552 | Pathogenic / likely pathogenic (★★★) | |
| KRAS P34L | 34 | Effector region | Pathogenic / likely pathogenic (★★★) |
| PTPN11 Y62C | 62 | SH2 1 | Pathogenic / likely pathogenic (★★★) |
| PTPN11 N308D | 308 | Tyrosine-protein phosphatase | Pathogenic / likely pathogenic (★★★) |
| PTPN11 M504V | 504 | Tyrosine-protein phosphatase | Pathogenic / likely pathogenic (★★★) |
| RAF1 P261S | 261 | Pathogenic / likely pathogenic (★★★) | |
| NRAS T58I | 58 | Pathogenic / likely pathogenic (★★★) | |
| PTPN11 Y63C | 63 | SH2 1 | Pathogenic / likely pathogenic (★★★) |
| SOS1 S548R | 548 | PH | Pathogenic / likely pathogenic (★★★) |
| KRAS T58I | 58 | Pathogenic / likely pathogenic (★★★) | |
| RAF1 S257L | 257 | Pathogenic / likely pathogenic (★★★) | |
| HRAS G13C | 13 | Pathogenic / likely pathogenic (★★★) | |
| PTPN11 E139D | 139 | SH2 2 | Pathogenic / likely pathogenic (★★★) |
| SOS1 E108K | 108 | Pathogenic / likely pathogenic (★★★) | |
| SOS1 K170E | 170 | Pathogenic / likely pathogenic (★★★) | |
| SOS1 E846K | 846 | Ras-GEF | Pathogenic / likely pathogenic (★★★) |
| SOS1 K163E | 163 | Pathogenic / likely pathogenic (★★★) | |
| NRAS G13V | 13 | Pathogenic / likely pathogenic (★★) | |
| PTPN11 D61V | 61 | SH2 1 | Pathogenic / likely pathogenic (★★) |
| PTPN11 D61G | 61 | SH2 1 | Pathogenic / likely pathogenic (★★) |
| PTPN11 Y62N | 62 | SH2 1 | Pathogenic / likely pathogenic (★★) |
| PTPN11 F71L | 71 | SH2 1 | Pathogenic / likely pathogenic (★★) |
| PTPN11 F285L | 285 | Tyrosine-protein phosphatase | Pathogenic / likely pathogenic (★★) |
| PTPN11 S502L | 502 | Tyrosine-protein phosphatase | Pathogenic / likely pathogenic (★★) |
| RIT1 A77P | 77 | Pathogenic / likely pathogenic (★★) | |
| RIT1 A77S | 77 | Pathogenic / likely pathogenic (★★) | |
| SOS1 I437S | 437 | Pathogenic / likely pathogenic (★★) | |
| NRAS G13R | 13 | Pathogenic / likely pathogenic (★★) | |
| RIT1 A77G | 77 | Pathogenic / likely pathogenic (★★) | |
| RIT1 A77T | 77 | Pathogenic / likely pathogenic (★★) | |
| RIT1 E81G | 81 | Pathogenic / likely pathogenic (★★) | |
| RIT1 F82I | 82 | Pathogenic / likely pathogenic (★★) | |
| RIT1 F82C | 82 | Pathogenic / likely pathogenic (★★) | |
| RIT1 F82L | 82 | Pathogenic / likely pathogenic (★★) | |
| RIT1 M90I | 90 | Pathogenic / likely pathogenic (★★) | |
| SOS2 T264K | 264 | DH | Pathogenic / likely pathogenic (★★) |
| SOS2 T264R | 264 | DH | Pathogenic / likely pathogenic (★★) |
| SOS2 M267R | 267 | DH | Pathogenic / likely pathogenic (★★) |
| SOS2 M267T | 267 | DH | Pathogenic / likely pathogenic (★★) |
| KRAS P34R | 34 | Effector region | Pathogenic / likely pathogenic (★★) |
| KRAS E153V | 153 | Pathogenic / likely pathogenic (★★) | |
| PTPN11 N58H | 58 | SH2 1 | Pathogenic / likely pathogenic (★★) |
| PTPN11 N58K | 58 | SH2 1 | Pathogenic / likely pathogenic (★★) |
| PTPN11 D61A | 61 | SH2 1 | Pathogenic / likely pathogenic (★★) |
| PTPN11 F71V | 71 | SH2 1 | Pathogenic / likely pathogenic (★★) |
| PTPN11 T73L | 73 | SH2 1 | Pathogenic / likely pathogenic (★★) |
| PTPN11 T73P | 73 | SH2 1 | Pathogenic / likely pathogenic (★★) |
| PTPN11 E76A | 76 | SH2 1 | Pathogenic / likely pathogenic (★★) |
| PTPN11 E76Q | 76 | SH2 1 | Pathogenic / likely pathogenic (★★) |
| PTPN11 N200Y | 200 | SH2 2 | Pathogenic / likely pathogenic (★★) |
| PTPN11 F285C | 285 | Tyrosine-protein phosphatase | Pathogenic / likely pathogenic (★★) |
| PTPN11 V428L | 428 | Tyrosine-protein phosphatase | Pathogenic / likely pathogenic (★★) |
| PTPN11 S502T | 502 | Tyrosine-protein phosphatase | Pathogenic / likely pathogenic (★★) |
| PTPN11 G503E | 503 | Tyrosine-protein phosphatase | Pathogenic / likely pathogenic (★★) |
| RAF1 R256G | 256 | Pathogenic / likely pathogenic (★★) | |
| RAF1 R256S | 256 | Pathogenic / likely pathogenic (★★) |
Showing 60 of 164.
Uncertain variants prioritized for review in Noonan syndrome
| Variant | Position | Protein part | Clinical label | Evidence |
|---|---|---|---|---|
| SOS1 M269V | 269 | DH | Conflicting reports (★) | +7: 3 other pathogenic changes within 3 positions; M269T at the same position is pathogenic; seen in 1.4e-06 of gnomAD DNA copies; REVEL 0.788 |
Which prediction tools work for Noonan syndrome
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- REVEL: 96 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- AlphaMissense: 95 out of 100
- CATVariant: 94 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- ESM1b (LLR): 90 out of 100
- AlphaGenome (regulatory): 89 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MutPred: 89 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaSVM: 88 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaLR: 85 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CADD: 85 out of 100
- PolyPhen-2: 82 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- EVE: 81 out of 100
- phyloP: 78 out of 100
- SIFT: 77 out of 100
- Pangolin: 54 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- SpliceAI: 51 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- DMS / MaveDB: 46 out of 100
- AlphaGenome (splicing): 39 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Same protein, different disease
- RASopathy also has ClinVar records linked to PTPN11 variants; they fall in the same places as the Noonan syndrome variants (51 pathogenic / likely pathogenic).
- Noonan syndrome and Noonan-related syndrome also has ClinVar records linked to PTPN11 variants; they fall in the same places as the Noonan syndrome variants (29 pathogenic / likely pathogenic).
- LEOPARD syndrome also has ClinVar records linked to PTPN11 variants; they fall partly in the same places as the Noonan syndrome variants (16 pathogenic / likely pathogenic).
- Metachondromatosis also has ClinVar records linked to PTPN11 variants; they fall in the same places as the Noonan syndrome variants (11 pathogenic / likely pathogenic).
- Monogenic short statue also has ClinVar records linked to PTPN11 variants; they fall in the same places as the Noonan syndrome variants (6 pathogenic / likely pathogenic).
- RASopathy also has ClinVar records linked to SOS1 variants; they fall partly in the same places as the Noonan syndrome variants (22 pathogenic / likely pathogenic).
- Noonan syndrome and Noonan-related syndrome also has ClinVar records linked to SOS1 variants; they fall in the same places as the Noonan syndrome variants (9 pathogenic / likely pathogenic).
- Noonan syndrome and Noonan-related syndrome also has ClinVar records linked to RIT1 variants; they fall mostly in different places as the Noonan syndrome variants (9 pathogenic / likely pathogenic).
- RASopathy also has ClinVar records linked to KRAS variants; they fall partly in the same places as the Noonan syndrome variants (23 pathogenic / likely pathogenic).
- Cardiofaciocutaneous syndrome also has ClinVar records linked to KRAS variants; they fall partly in the same places as the Noonan syndrome variants (9 pathogenic / likely pathogenic).
- Autoimmune lymphoproliferative syndrome also has ClinVar records linked to KRAS variants; they fall mostly in different places as the Noonan syndrome variants (5 pathogenic / likely pathogenic).
- Non-small cell lung carcinoma also has ClinVar records linked to KRAS variants; they fall mostly in different places as the Noonan syndrome variants (5 pathogenic / likely pathogenic).
- Vascular malformation also has ClinVar records linked to KRAS variants; they fall mostly in different places as the Noonan syndrome variants (4 pathogenic / likely pathogenic).
- RASopathy also has ClinVar records linked to RAF1 variants; they fall partly in the same places as the Noonan syndrome variants (28 pathogenic / likely pathogenic).
- Dilated cardiomyopathy 1NN also has ClinVar records linked to RAF1 variants; they fall mostly in different places as the Noonan syndrome variants (5 pathogenic / likely pathogenic).
- Noonan syndrome and Noonan-related syndrome also has ClinVar records linked to RAF1 variants; they fall partly in the same places as the Noonan syndrome variants (4 pathogenic / likely pathogenic).
- RASopathy also has ClinVar records linked to BRAF variants; they fall partly in the same places as the Noonan syndrome variants (36 pathogenic / likely pathogenic).
- Cardio-facio-cutaneous syndrome also has ClinVar records linked to BRAF variants; they fall partly in the same places as the Noonan syndrome variants (26 pathogenic / likely pathogenic).
- Cardiofaciocutaneous syndrome also has ClinVar records linked to BRAF variants; they fall mostly in different places as the Noonan syndrome variants (17 pathogenic / likely pathogenic).
- Noonan syndrome and Noonan-related syndrome also has ClinVar records linked to BRAF variants; they fall in the same places as the Noonan syndrome variants (10 pathogenic / likely pathogenic).
- Non-small cell lung carcinoma also has ClinVar records linked to BRAF variants; they fall in the same places as the Noonan syndrome variants (9 pathogenic / likely pathogenic).
Diseases related to Noonan syndrome
- Hypertrophic cardiomyopathy, also linked to ARAF, BRAF, FGA, FGB and 12 more
- Costello syndrome, also linked to ARAF, BRAF, FGA, FGB and 11 more
- RASopathy, also linked to BRAF, CBL, HRAS, KRAS and 8 more
- Noonan syndrome and Noonan-related syndrome, also linked to BRAF, CBL, HRAS, KRAS and 8 more
- Cardiofaciocutaneous syndrome, also linked to BRAF, KRAS, MAP2K1, MAP2K2 and 1 more
- Cardio-facio-cutaneous syndrome, also linked to BRAF, KRAS, MAP2K1 and MAP2K2
- Colorectal cancer, also linked to BRAF, KRAS, NRAS and PIK3CA
- Non-small cell lung carcinoma, also linked to BRAF, KRAS, MAP2K1 and PIK3CA
- Vascular malformation, also linked to BRAF, KRAS, MAP2K1 and NRAS
- Myelomonocytic leukemia, also linked to CBL, KRAS, NRAS and PTPN11
- Melanoma, also linked to BRAF, MAP2K1, MAP2K2 and NRAS
- Acute myeloid leukemia, also linked to KRAS, NRAS and PTPN11
Frequently asked questions
Which genes have records linked to Noonan syndrome?
This view contains 25 analyzed proteins: PTPN11, SOS1, RIT1, KRAS, RAF1 and 20 more. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 164 pathogenic or likely pathogenic variants, 800 variants of uncertain significance and 180 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 1 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 1,358 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center